CHESTNUT RIDGE, N.Y., Aug. 15, 2017 /PRNewswire/ -- BioHiTech Global, Inc. ("BioHiTech" or the "Company") (OTCQB: BHTG), a green technology company that develops and deploys innovative and disruptive waste management technologies, reported financial results for the second quarter of 2017 ended June 30, 2017.
Business Highlights
"We continue to lay the foundation for establishing our company as the premier provider of cost-effective and environmentally friendly technology solutions for waste management," said Frank E. Celli, CEO of BioHiTech. "We are excited about the initial response to the launch of our Revolution Series Digesters and believe these units will prove to be a game changer for the company in the coming years as we have now opened a large underserviced segment of the food service and hospitality market. We have also made tremendous progress in the quarter toward the development of a HEBioT facility in New York through the land purchase contract with New Windsor. New York state is the largest exporter of waste in the US and our proven technology provides a solution that can reduce landfill waste by as much as 80% in addition to producing solid recovered fuel. As we move through the remainder of 2017, we will continue to progressively deploy our technology solutions for waste and supply chain management as we work to drive accelerating revenue growth for the benefit of our stockholders."
Q2 Financial Highlights
Revenue: Revenue in Q2 2017 was $549,000, a 22% increase compared to revenue of $451,000 in Q2 2016. Recurring rental, service and maintenance grew by 11% and represented 67% of total revenue. Revenue from equipment sales rose by 53% to reach $182,000. This significant improvement in equipment sales was primarily due to an increase in reseller activity supporting educational and hospitality customers.
Gross Profit: Q2 2017 gross profit was $170,000, an 89% increase compared to gross profit of $90,000 in Q2 2016. Gross profit margin increased by 11 percentage points to reach 31%. Rental, service and maintenance gross profit margin increased by 3 percentage points to 26%. Equipment sales gross profit margin increased 31 percentage points to reach 42% due to increased domestic sales and a change in the models sold.
Operating Expenses: Q2 2017 operating expenses increased by 3% to $1.7 million compared to $1.6 million in Q2 2016. The increase was primarily driven by a continued focus on professional services supporting investor relations and marketing, offset in part by a decrease in SG&A.
Operating Loss: Q2 2017 operating loss improved by 3% to a loss of $1.5 million due to increased gross profit offset by a lesser increase in operating expenses.
Net Loss: Q2 2017 net loss was $1.9 million, a 9% increase compared to net loss of $1.7 million in Q2 2016. The increase in net loss was due to an increase in interest expense in excess of the improvement in operating loss.
Year to Date June 30, 2017
Revenue: In the first half, 2017 revenue was $1,140,000, a 25% increase compared to revenue of $914,000 in 2016. Recurring rental, service and maintenance grew by 14% and represented 64% of total revenue. Revenue from equipment sales rose by 50% to reach $415,000. This significant improvement in equipment sales was primarily due to an increase in reseller activity supporting educational and hospitality customers in the second quarter and international activity in the first quarter.
Gross Profit: In the first half, 2017 gross profit was $369,000, an 81% increase compared to gross profit of $204,000 in Q2 2016. Gross profit margin increased by 10 percentage points to reach 32%. Rental, service and maintenance gross profit margin increased by 6 percentage points to 27%. Equipment sales gross profit margin increased 16 percentage points to reach 42% due to increased domestic sales and a change in the models sold.
Operating Expenses: In the first half, 2017 operating expenses increased by 12% to $3.6 million compared to $3.2 million in 2016. The increase was primarily driven by a continued focus on professional services supporting investor relations and marketing, offset in part by a decrease in SG&A.
Operating Loss: In the first half, 2017 operating loss increased by 8% to a loss of $3.2 million due to increased operating expenses relating to professional services supporting investor relations offset in part by decreases in other professional fees and SG&A. Net cash used in operating activities decreased to $2.2 million in the six months ended June 2017 compared to $3.0 million in the six months ended June 2016.
Net Loss: In the first half, 2017 net loss was $3.9 million, a 17% increase compared to net loss of $3.3 million in 2016. The increase in net loss was due to an increase in interest expense and an increase in the operating loss.
Brian C. Essman, CFO commented, "We are pleased to have achieved continued quarter over quarter top line revenue growth in Q2 2017. More importantly, gross profit margin expanded for both rental and equipment sales. SG&A expenses decreased slightly in Q2 2017 and net cash used in operating activities decreased substantially as we continue to work to prudently manage our resources while we grow our business. We expect our Revolution Series digesters to begin contributing revenue in Q4 2017 and to build progressively throughout 2018. As we move through the second half of 2017, we intend to continue to move forward with our aggressive long term growth plans to deliver substantial value for our stockholders."
About BioHiTech Global
BioHiTech Global (OTCQB: BHTG), "The Company" headquartered in Chestnut Ridge NY, develops and deploys innovative and disruptive waste management technologies. The combined offerings of BioHiTech Global offer our customers a full suite of technology based disposal options capable of having a significant impact on waste generation while providing a true zero landfill environment. With options for both on and off site biological treatment of waste, BioHiTech Global is a leader in zero waste solutions for businesses and municipalities. For more information, please visit www.biohitechglobal.com.
Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of BioHiTech Global, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. BioHiTech Global, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission ("SEC"). There may be other factors not mentioned above or included in the BioHiTech's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. BioHiTech Global, Inc. assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Company Contact:
BioHiTech Global, Inc.
Lisa Giovannielli
Director, Corporate Communications
Direct: 845-262-1081
[email protected]
www.biohitechglobal.com
BioHiTech Global, Inc. and Subsidiaries | ||||||||||||
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) | ||||||||||||
Three Months Ended June 30, |
Six Months Ended June 30, | |||||||||||
2017 |
2016 |
2017 |
2016 | |||||||||
Revenue |
||||||||||||
Rental, service and maintenance |
$ |
366,812 |
$ |
331,692 |
$ |
725,348 |
$ |
637,555 | ||||
Equipment sales |
182,405 |
119,589 |
414,549 |
276,454 | ||||||||
Total revenue |
549,217 |
451,281 |
1,139,897 |
914,009 | ||||||||
Cost of revenue |
||||||||||||
Rental, service and maintenance |
272,757 |
254,617 |
531,697 |
505,727 | ||||||||
Equipment sales |
106,664 |
106,717 |
239,154 |
204,173 | ||||||||
Total Cost of revenue |
379,421 |
361,334 |
770,851 |
709,900 | ||||||||
Gross profit |
169,796 |
89,947 |
369,046 |
204,109 | ||||||||
Operating expenses |
||||||||||||
Selling, general and administrative |
1,057,223 |
1,159,598 |
2,121,852 |
2,188,248 | ||||||||
Research and development |
216,822 |
235,164 |
404,324 |
419,095 | ||||||||
Professional fees |
364,227 |
201,889 |
1,013,850 |
537,734 | ||||||||
Depreciation and amortization |
28,335 |
29,174 |
58,107 |
54,948 | ||||||||
Total operating expenses |
1,666,607 |
1,625,825 |
3,598,133 |
3,200,025 | ||||||||
Loss from operations |
(1,496,811) |
(1,535,878) |
(3,229,087) |
(2,995,916) | ||||||||
Other expense (income) |
||||||||||||
Equity loss in affiliate |
5,916 |
- |
5,916 |
- | ||||||||
Loss on change in fair value of warrants |
1,999 |
- |
1,999 |
- | ||||||||
Interest income |
- |
(2,713) |
- |
(3,068) | ||||||||
Interest expense |
374,175 |
185,566 |
670,432 |
334,725 | ||||||||
Total other expense |
382,090 |
182,853 |
678,347 |
331,657 | ||||||||
Net loss |
(1,878,901) |
(1,718,731) |
(3,907,434) |
(3,327,573) | ||||||||
Other comprehensive (loss) income |
||||||||||||
Foreign currency translation adjustment |
(21,340) |
(1,506) |
(28,504) |
6,400 | ||||||||
Comprehensive loss |
$ |
(1,900,241) |
$ |
(1,720,237) |
$ |
(3,935,938) |
$ |
(3,321,173) | ||||
Net loss per share - basic and diluted |
$ |
(0.23) |
$ |
(0.21) |
$ |
(0.47) |
$ |
(0.40) | ||||
Weighted average number of common shares |
8,322,086 |
8,229,712 |
8,276,154 |
8,229,712 |
BioHiTech Global, Inc. and Subsidiaries | ||||||||
Condensed Consolidated Balance Sheets (Unaudited) | ||||||||
June 30, |
December 31, |
|||||||
2017 |
2016 |
|||||||
Assets |
||||||||
Current Assets |
||||||||
Cash |
$ |
150,457 |
$ |
325,987 |
||||
Accounts receivable, net |
137,173 |
140,130 |
||||||
Inventory |
410,663 |
706,017 |
||||||
Prepaid expenses and other current assets |
44,782 |
21,865 |
||||||
Total Current Assets |
743,075 |
1,193,999 |
||||||
Equipment on operating leases, net |
1,178,007 |
1,023,404 |
||||||
Equipment, fixtures and vehicles, net |
48,098 |
54,356 |
||||||
Intangible assets, net |
219,233 |
267,042 |
||||||
Investment in Entsorga West Virginia, LLC |
1,028,112 |
- |
||||||
MBT facility development costs |
74,966 |
- |
||||||
Other assets |
13,500 |
13,500 |
||||||
Total Assets |
$ |
3,304,991 |
$ |
2,552,301 |
||||
Liabilities and Stockholders' Deficit |
||||||||
Current Liabilities: |
||||||||
Line of credit |
$ |
2,463,736 |
$ |
2,463,736 |
||||
Accounts payable |
1,380,348 |
1,197,277 |
||||||
Accrued expenses |
584,086 |
522,727 |
||||||
Accrued interest payable |
733,397 |
411,917 |
||||||
Accrued interest payable in cash or common stock |
389,333 |
- |
||||||
Deferred revenue |
88,384 |
61,879 |
||||||
Notes payable |
100,000 |
100,000 |
||||||
Notes payable - related party |
275,000 |
275,000 |
||||||
Convertible note, net of deferred financing cost of $12,982 and original issue discounts of $47,007 |
160,011 |
- |
||||||
Convertible notes, including related party of $640,000, net of original issue discounts of $219,265 |
720,735 |
- |
||||||
Advance from related party |
593,527 |
1,213,027 |
||||||
Customer deposits |
30,094 |
36,131 |
||||||
Long-term debt, current portion |
7,143 |
8,525 |
||||||
Total Current Liabilities |
7,525,794 |
6,290,219 |
||||||
Promissory note - related party |
4,500,000 |
2,500,000 |
||||||
Long-term debt, net of current portion |
8,201 |
11,048 |
||||||
Long-term accrued interest payable in cash or common stock |
86,485 |
253,000 |
||||||
Unsecured subordinated mandatorily convertible notes, including related parties of 1,750,000, and $3,800,000, net of deferred financing costs of $69,898 and $118,866 as of June 30, 2017 and December 31, 2016, respectively |
5,655,102 |
4,956,134 |
||||||
Total Liabilities |
17,775,582 |
14,010,401 |
||||||
Commitments and Contingencies |
||||||||
Stockholders' Deficit |
||||||||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued |
- |
- |
||||||
Common stock, $0.0001 par value, 40,000,000 shares authorized, 8,352,712 shares issued and outstanding as of June 30, 2017; 20,000,000 shares authorized, 8,229,712 shares issued and outstanding as of December 31, 2016 |
835 |
823 |
||||||
Additional paid in capital |
10,527,759 |
9,604,324 |
||||||
Accumulated deficit |
(24,979,600) |
(21,072,166) |
||||||
Accumulated other comprehensive (loss) gain |
(19,585) |
8,919 |
||||||
Total Stockholders' Deficit |
(14,470,591) |
(11,458,100) |
||||||
Total Liabilities and Stockholders' Deficit |
$ |
3,304,991 |
$ |
2,552,301 |
BioHiTech Global, Inc. and Subsidiaries | ||||||||
Condensed Consolidated Statements of Cash Flows (Unaudited) | ||||||||
Six Months Ended June 30, |
||||||||
2017 |
2016 |
|||||||
Cash flows from operating activities: |
||||||||
Net loss: |
$ |
(3,907,434) |
$ |
(3,327,573) |
||||
Adjustments to reconcile net loss to net cash used in operations: |
||||||||
Depreciation and amortization |
202,064 |
205,268 |
||||||
Provision (recovery) - bad debts |
29,212 |
61,743 |
||||||
Stock based employee compensation |
230,981 |
350,632 |
||||||
Fees paid in stock and warrants |
518,267 |
- |
||||||
Interest resulting from amortization of financing costs and discounts |
71,903 |
- |
||||||
Equity loss in affiliate |
5,916 |
|||||||
Change in fair value of warrant liability |
1,999 |
|||||||
Changes in operating assets and liabilities |
693,725 |
(269,317) |
||||||
Net cash used in operations |
(2,153,367) |
(2,979,247) |
||||||
Cash flow from investing activities: |
||||||||
Sale of used machinery and equipment |
13,352 |
- |
||||||
Investment in Entsorga West Virginia, LLC |
(1,034,027) |
- |
||||||
Increase in MBT facility development costs |
(74,966) |
- |
||||||
Purchases of equipment, fixtures and vehicles |
(4,040) |
(3,825) |
||||||
Net cash used in investing activities |
(1,099,681) |
(3,825) |
||||||
Cash flows from financing activities: |
||||||||
Net change in line of credit |
- |
(25,017) |
||||||
Proceeds from convertible notes with warrants and beneficial conversion feature |
200,000 |
- |
||||||
Proceeds from series convertible notes with warrants and beneficial conversion feature |
270,000 |
|||||||
Proceeds from series convertible notes |
150,000 |
3,250,000 |
||||||
Deferred financing costs incurred |
(16,000) |
(132,391) |
||||||
Repayments of long-term debt |
(4,228) |
(4,097) |
||||||
Related party: |
||||||||
Net decrease in advances |
1,169,527 |
(531,973) |
||||||
Proceeds from promissory notes |
786,973 |
790,000 |
||||||
Repayments of promissory notes |
- |
(200,000) |
||||||
Proceeds from convertible notes |
500,000 |
- |
||||||
Net cash provided by financing activities |
3,056,272 |
3,146,522 |
||||||
Effect of exchange rate on cash |
21,246 |
27,473 |
||||||
Net change in cash |
(175,530) |
190,923 |
||||||
Cash - beginning of period |
325,987 |
39,196 |
||||||
Cash - end of period |
$ |
150,457 |
$ |
230,119 |
SOURCE BioHiTech Global, Inc.